CSPC Pharmaceutical Group Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	26,006	29,009	31,450	30,937	27,867
Revenue Growth (YoY)	-10.35%	-7.76%	1.66%	11.02%	11.73%
Cost of Revenue	8,947	8,711	9,273	8,680	6,732
Gross Profit	17,059	20,299	22,177	22,256	21,135
Selling, General & Admin	7,289	9,742	10,330	11,510	11,453
Research & Development	5,809	5,191	4,830	3,987	3,433
Operating Expenses	13,097	14,933	15,161	15,497	14,886
Operating Income	3,961	5,366	7,016	6,760	6,249
Interest Expense	-38.6	-43.67	-25.9	-24.89	-7.66
Interest & Investment Income	195.87	232.5	259.88	242.53	183.24
Earnings From Equity Investments	-52.45	-89.47	-54.2	-15.4	22.44
Currency Exchange Gain (Loss)	-33.91	19.79	102.53	118.13	-35.96
Other Non Operating Income (Expenses)	457.13	221.31	246.21	315.32	172.63
EBT Excluding Unusual Items	4,489	5,707	7,545	7,395	6,584
Gain (Loss) on Sale of Investments	335.5	-104.47	-90.62	266.41	323.94
Gain (Loss) on Sale of Assets	-16.47	-23.4	-22.23	-7.36	-10.79
Asset Writedown	-	-	-42.32	-72.11	-50
Pretax Income	4,808	5,579	7,389	7,582	6,847
Income Tax Expense	931.73	1,240	1,317	1,350	1,159
Earnings From Continuing Operations	3,876	4,339	6,073	6,232	5,688
Minority Interest in Earnings	5.72	-10.79	-199.37	-140.66	-82.94
Net Income	3,882	4,328	5,873	6,091	5,605
Net Income to Common	3,882	4,328	5,873	6,091	5,605
Net Income Growth	-10.30%	-26.31%	-3.58%	8.67%	8.63%
Shares Outstanding (Basic)	11,424	11,738	11,872	11,917	11,953
Shares Outstanding (Diluted)	11,424	11,738	11,873	11,919	11,954
Shares Change (YoY)	-2.68%	-1.14%	-0.38%	-0.29%	-0.01%
EPS (Basic)	0.34	0.37	0.49	0.51	0.47
EPS (Diluted)	0.34	0.37	0.49	0.51	0.47
EPS Growth	-7.84%	-25.47%	-3.21%	9.00%	8.64%
Free Cash Flow	-	2,519	2,555	5,407	3,226
Free Cash Flow Per Share	-	0.21	0.21	0.45	0.27
Dividend Per Share	0.261	0.244	0.258	0.191	0.152
Dividend Growth	6.66%	-5.30%	35.08%	25.66%	41.58%
Gross Margin	65.59%	69.97%	70.51%	71.94%	75.84%
Operating Margin	15.23%	18.50%	22.31%	21.85%	22.43%
Profit Margin	14.93%	14.92%	18.68%	19.69%	20.11%
Free Cash Flow Margin	-	8.69%	8.12%	17.48%	11.58%
EBITDA	5,046	6,451	7,934	7,611	6,974
EBITDA Margin	19.40%	22.24%	25.23%	24.60%	25.02%
D&A For EBITDA	1,085	1,085	918.47	851.62	724.39
EBIT	3,961	5,366	7,016	6,760	6,249
EBIT Margin	15.23%	18.50%	22.31%	21.85%	22.43%
Effective Tax Rate	19.38%	22.23%	17.82%	17.81%	16.93%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.